NEW YORK The Deal -- Blue Bell, Pa.-based Inovio Pharmaceuticals (INO - Get Report), has out-licensed two preclinical DNA immunotherapies, for prostate cancer and hepatitis B, plus a technology platform to Swiss drugs giant Roche Holdings.Roche will make a $10 million up-front payment to Inovio with development and commercial milestones of up to $412.5 million for an exclusive worldwide license to the drug candidates and exclusive use of Inovio's Cellectra electroporation technology for delivery of the vaccines. Roche also has an option to license additional vaccines for cancers.
The Deal: Roche Cuts Deal With Inovio for Cancer, Hep B Therapies
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.